Status:
ACTIVE_NOT_RECRUITING
Nanoparticle for DSA Removal
Lead Sponsor:
University of Zurich
Conditions:
Kidney Failure
Presence of Donor Specific Antibodies
Eligibility:
All Genders
18+ years
Brief Summary
Magnetic nanoparticles, coated with human leukocyte antigens (HLA) to capture anti-HLA antibodies with donor specificity (donor-specific antibodies, DSA), will be tested ex-vivo.
Detailed Description
This project aims at developing a new method using human leukocyte antigens (HLA)-coated magnetic nanoparticles to remove donor-specific antibodies (DSA) from the patients' blood ex vivo, while trying...
Eligibility Criteria
Inclusion
- DSA in the blood as detected by Luminex®
- Adults (\>18 years old)
- Informed written consent
Exclusion
- Inability to follow the procedures of the study, due to language problems, psychological disorders, social conditions or dementia
- Pregnancy and/or breast feeding
- Unwillingness to participate in this study
Key Trial Info
Start Date :
October 5 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04277377
Start Date
October 5 2021
End Date
February 28 2026
Last Update
August 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zurich, Division of Anaesthesiology
Zurich, Canton of Zurich, Switzerland, 8091